Biotech Stocks
Track and analyze companies developing breakthrough therapies and innovative biotechnology solutions
# | Company | Price | Market Cap | Biotech Angle | Tags |
---|---|---|---|---|---|
1 |
![]() Amgen Inc.
AMGN
|
$291.16 | $156.51B | Leading biologic medicines developer | Oncology Immunology Cardiovascular |
2 |
![]() Gilead Sciences, Inc.
GILD
|
$104.08 | $129.71B | Antiviral and oncology therapeutics | HIV Oncology Cell Therapy |
3 |
![]() Vertex Pharmaceuticals Incorporated
VRTX
|
$459 | $118.21B | Cystic fibrosis treatments leader | Rare Disease Gene Editing Pipeline |
4 |
![]() Regeneron Pharmaceuticals, Inc.
REGN
|
$673.6 | $72.42B | Antibody therapeutics platform | Immunology Oncology Eye Disease |
5 |
![]() Seagen Inc.
SGEN
|
$228.74 | $43.15B | Antibody-drug conjugate technology | Oncology ADC Pipeline |
6 |
![]() Alnylam Pharmaceuticals, Inc.
ALNY
|
$256.45 | $33.08B | RNAi therapeutics pioneer | RNAi Rare Disease Pipeline |
7 |
![]() BioNTech SE
BNTX
|
$119.83 | $28.73B | mRNA and immunotherapy platform | mRNA Oncology Vaccines |
8 |
![]() BeiGene, Ltd.
BGNE
|
$184.71 | $20.21B | Global oncology therapeutics | Oncology China Pipeline |
9 |
![]() Incyte Corporation
INCY
|
$70.42 | $13.63B | JAK inhibitors and oncology | Oncology Immunology JAK |
10 |
![]() Moderna, Inc.
MRNA
|
$32.99 | $12.70B | mRNA therapeutics platform | mRNA Vaccines Oncology |
11 |
![]() Sarepta Therapeutics, Inc.
SRPT
|
$107.95 | $10.31B | Genetic medicine for rare diseases | Gene Therapy Rare Disease DMD |
12 |
![]() CRISPR Therapeutics AG
CRSP
|
$49.72 | $4.26B | CRISPR gene editing platform | Gene Editing CRISPR Pipeline |
13 |
![]() Recursion Pharmaceuticals, Inc.
RXRX
|
$10.53 | $4.04B | AI-powered drug discovery | AI Platform Pipeline |
14 |
![]() Denali Therapeutics Inc.
DNLI
|
$21.37 | $3.08B | Neurodegenerative disease focus | Neurology Pipeline Protein |
15 |
![]() Beam Therapeutics Inc.
BEAM
|
$32.4 | $2.68B | Base editing technology | Gene Editing Base Editing Pipeline |
16 |
![]() Kymera Therapeutics, Inc.
KYMR
|
$36.88 | $2.39B | Protein degradation platform | Protein Oncology Pipeline |
17 |
![]() Arvinas, Inc.
ARVN
|
$18.31 | $1.26B | Protein degradation therapeutics | Protein Oncology Pipeline |
18 |
![]() Intellia Therapeutics, Inc.
NTLA
|
$10.7 | $1.09B | In vivo CRISPR therapeutics | Gene Editing CRISPR Pipeline |
19 |
![]() AbCellera Biologics Inc.
ABCL
|
$3.27 | $965.85M | AI-powered antibody discovery | AI Antibodies Platform |
20 |
![]() Intercept Pharmaceuticals, Inc.
ICPT
|
$19 | $794.69M | Liver disease therapeutics | Liver NASH Pipeline |
21 |
![]() Fate Therapeutics, Inc.
FATE
|
$1.42 | $161.73M | Cell therapy platform | Cell Therapy Oncology Pipeline |
22 |
![]() Editas Medicine, Inc.
EDIT
|
$1.38 | $113.92M | CRISPR gene editing therapies | Gene Editing CRISPR Pipeline |
23 |
![]() bluebird bio, Inc.
BLUE
|
$7.27 | $70.68M | Gene therapy for rare diseases | Gene Therapy Rare Disease Pipeline |
24 |
![]() Arena Pharmaceuticals, Inc.
ARNA
|
$99.99 | $- | Small molecule therapeutics | Small Molecule Pipeline Immunology |
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129707&wire=1 or contact Joseph E. Levi, Esq.

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) and certain of its officers.

Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.

Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129654&wire=1 or contact Joseph E. Levi, Esq.

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal challenges, analysts TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230.

Moderna (MRNA) Q4 2024 Earnings Call Transcript
Moderna (NASDAQ:MRNA ) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Ellie Merle - UBS Gena Wang - Barclays Michael Yee - Jefferies Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Tyler Van Buren - TD Cowen Luca Issi - RBC Capital Courtney Breen - Bernstein Edward Tenthoff - Piper Sandler Jessica Fye - J.P. Morgan Simon Baker - Redburn Atlantic Myles Minter - William Blair Tim Anderson - Bank of America Operator Good day, and thank you for standing by.

Moderna shares rise on quarterly revenue beat despite wider-than-expected loss
Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported a wider-than-expected loss per share of $2.91, compared to estimates of a loss per share of $2.73.

Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , Feb. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) have opportunity to lead the securities fraud class action lawsuit.

Moderna's Q4 Loss Wider Than Expected
Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.

Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) should contact Levi & Korsinsky about pending Class Action - REGN
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129622&wire=1 or contact Joseph E. Levi, Esq.

Moderna has no 'visible path' to profitability, analyst says
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expected loss per share of $2.91. Jefferies Biotech Analyst Michael Yee speaks with Brad Smith and Madison Mills on the Morning Brief on Moderna's release, commenting that the drugmaker continues to "[remain] in a very challenging position" as the path to profitability falls out of sight.

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.

Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129601&wire=1 or contact Joseph E. Levi, Esq.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.

Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129461&wire=1 or contact Joseph E. Levi, Esq.

REGN Shareholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

Moderna beats on revenue but loses more than expected as it scales down manufacturing
Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage pipeline and cost reduction efforts.

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.

Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.

Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129372&wire=1 or contact Joseph E. Levi, Esq.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129361&wire=1 or contact Joseph E. Levi, Esq.

Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share.

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO Tolga Tanguler - Chief Commercial Officer Pushkal Garg - CMO Jeff Poulton - CFO Christine Lindenboom - Chief Corporate Communications Officer Conference Call Participants Tazeen Ahmad - Bank of America Kostas Biliouris - BMO Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies Ritu Baral - TD Cowen Teraesa Vitelli - Scotiabank Gary Nachman - Raymond James Jessica Fye - JPMorgan Paul Matteis - Stifel Salveen Richter - Goldman Sachs Ellie Merle - UBS Mani Foroohar - Leerink Partners Luca Issi - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Fourth Quarter Full Year 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Investors Who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Should Contact Levi & Korsinsky About Pending Class Action - REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129320&wire=1 or contact Joseph E. Levi, Esq.

Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 2, 2023 and October 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 10, 2025.

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129263&wire=1 or contact Joseph E. Levi, Esq.

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129204&wire=1 or contact Joseph E. Levi, Esq.

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can b.

Frequently Asked Questions
- Therapeutics - Novel drug development
- Gene Therapy - Genetic disease treatment
- Cell Therapy - Cellular treatments
- Immunotherapy - Immune system targeting
- Precision Medicine - Personalized treatments
- AMGN - Amgen Inc.
- GILD - Gilead Sciences, Inc.
- VRTX - Vertex Pharmaceuticals Incorporated
- REGN - Regeneron Pharmaceuticals, Inc.
- SGEN - Seagen Inc.
- Oncology - Cancer treatments
- Rare Diseases - Orphan drugs
- Gene Editing - CRISPR and beyond
- Immunology - Immune disorders
- Neuroscience - Brain disorders
- Breakthrough potential
- Large market opportunities
- Patent protection
- M&A activity
- Aging demographics
- Clinical trial results
- FDA approvals
- Patent decisions
- Market size
- Competition
- Funding environment